| Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data M Gertz, A Harrison, JB Houston, A Galetin Drug Metabolism and Disposition 38 (7), 1147-1158, 2010 | 334 | 2010 |
| Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data PJ Kilford, M Gertz, JB Houston, A Galetin Drug Metabolism and Disposition 36 (7), 1194-1197, 2008 | 162 | 2008 |
| Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential M Gertz, CM Cartwright, MJ Hobbs, KE Kenworthy, M Rowland, ... Pharmaceutical research 30, 761-780, 2013 | 147 | 2013 |
| Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction M Gertz, JB Houston, A Galetin Drug metabolism and disposition 39 (9), 1633-1642, 2011 | 146 | 2011 |
| Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions A Galetin, M Gertz, JB Houston Drug metabolism and pharmacokinetics 25 (1), 28-47, 2010 | 135 | 2010 |
| Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions A Galetin, M Gertz, JB Houston Expert opinion on drug metabolism & toxicology 4 (7), 909-922, 2008 | 126 | 2008 |
| Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations M Gertz, PJ Kilford, JB Houston, A Galetin Drug Metabolism and Disposition 36 (3), 535-542, 2008 | 91 | 2008 |
| Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations M Gertz, JD Davis, A Harrison, JB Houston, A Galetin Current drug metabolism 9 (8), 785-795, 2008 | 79 | 2008 |
| Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction … M Gertz, N Tsamandouras, C Säll, JB Houston, A Galetin Pharmaceutical research 31, 2367-2382, 2014 | 55 | 2014 |
| Progress in prediction and interpretation of clinically relevant metabolic drug-drug interactions: a minireview illustrating recent developments and current opportunities S Fowler, PN Morcos, Y Cleary, M Martin-Facklam, N Parrott, M Gertz, ... Current pharmacology reports 3, 36-49, 2017 | 46 | 2017 |
| Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data KL Gill, M Gertz, JB Houston, A Galetin Drug Metabolism and Disposition 41 (4), 744-753, 2013 | 40 | 2013 |
| Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies L Docci, N Milani, T Ramp, AA Romeo, P Godoy, DO Franyuti, ... Lab on a Chip 22 (6), 1187-1205, 2022 | 35 | 2022 |
| In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages A Ufuk, F Assmus, L Francis, J Plumb, V Damian, M Gertz, JB Houston, ... Molecular pharmaceutics 14 (4), 1033-1046, 2017 | 25 | 2017 |
| Model‐based drug–drug interaction extrapolation strategy from adults to children: risdiplam in pediatric patients with spinal muscular atrophy Y Cleary, M Gertz, P Grimsey, A Günther, K Heinig, K Ogungbenro, ... Clinical Pharmacology & Therapeutics 110 (6), 1547-1557, 2021 | 24 | 2021 |
| Application of a gut–liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil N Milani, N Parrott, DO Franyuti, P Godoy, A Galetin, M Gertz, S Fowler Lab on a Chip 22 (15), 2853-2868, 2022 | 21 | 2022 |
| Model‐based assessments of cyp‐mediated drug–drug interaction risk of alectinib: physiologically based pharmacokinetic modeling supported clinical development Y Cleary, M Gertz, PN Morcos, L Yu, K Youdim, A Phipps, S Fowler, ... Clinical Pharmacology & Therapeutics 104 (3), 505-514, 2018 | 21 | 2018 |
| Global sensitivity analysis of the Rodgers and Rowland model for prediction of tissue: plasma partitioning coefficients: assessment of the key physiological and physicochemical … E Yau, A Olivares-Morales, M Gertz, N Parrott, AS Darwich, L Aarons, ... The AAPS journal 22, 1-13, 2020 | 18 | 2020 |
| Impact of permeability on in vitro predictions of intestinal availability in the QGut model M Gertz, KS Fenner, A Harrison, J Davis, JB Houston, A Galetin host publication, 2008 | 4 | 2008 |
| Estimation of FMO3 ontogeny by mechanistic population pharmacokinetic modelling of risdiplam and its impact on drug–drug interactions in children Y Cleary, H Kletzl, P Grimsey, K Heinig, K Ogungbenro, ... Clinical Pharmacokinetics 62 (6), 891-904, 2023 | 3 | 2023 |
| Investigation of simplified physiologically‐based pharmacokinetic models in rat and human E Yau, A Olivares‐Morales, K Ogungbenro, L Aarons, M Gertz CPT: Pharmacometrics & Systems Pharmacology 12 (3), 333-345, 2023 | 3 | 2023 |
Aleksandra GaletinProfessor of Translational Pharmacokinetics, University of Manchester, UKGeverifieerd e-mailadres voor manchester.ac.uk
